The US National Institutes of Health (NIH) has published two funding opportunity announcements (FOA) related to nasal delivery of CNS therapeutics. Both FOAs say that their purpose is to “is to develop a nasal delivery formulation that reliably delivers of a therapeutic (e.g., peptides, antibodies, RNAi, or pharmacotherapeutics), at a physiologically relevant concentration, into the central nervous system (CNS).
”The global market for direct-to-CNS-delivery technologies is reported to grow to $450 million by 2019, and has increased by 50% per year since 2013.”
MetP’s platform for nasal delivery of CNS therapeutics is fully developed and ready for commercial-scale production.
Its specific technology (“Silcum®”) essentially includes a symbiosis triangle:
- A versatile and stable semi-solid matrix suitable for the molecule chosen. The formulation is safe, virtually odorless and tasteless, and convenient to use. It has shown to deliver molecules to the CNS.
- A fingernail-sized single-dose container (“Lecticula®”) with high dosing accuracy (± 3%) and
- An appropriate filling machine (“Maxima®”) for the containers
Visit us at Interpack 2017 (May 04-10, 2017 in Duesseldorf/Germany).
MetP is presenting its technology at the “Harro Höfliger” Booth B15 in Hall 16 (www.hoefliger-interpack.com, www.hoefliger.com/unternehmen/netzwerk).